Linked Life Data

12353822

Source:http://linkedlifedata.com/resource/pubmed/id/12353822

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2002-9-30
pubmed:abstractText
Results from many randomized trials of adjuvant breast cancer therapy have been presented in several overviews and at subsequent meetings. This manuscript reviews the current status of both chemo- and endocrine therapy and the prospects for combination therapy, as summarized at the NIH and St Gallen Consensus meetings. In conclusion, treatment selection should be based primarily on endocrine responsiveness; however, a collaborative approach involving the development of new agents and investigation of their optimal integration into therapy programs will ensure progress and improved patient care.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0167-6806
pubmed:author
pubmed:issnType
Print
pubmed:volume
75 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S37-44; discussion S57-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?
pubmed:affiliation
Department of Surgical Oncology, University of Newcastle, NSW, Australia. john.forbes@anzbctg.newcastle.edu.au
pubmed:publicationType
Journal Article, Review